IMCRImmunocore Holdings plc
- GlobeNewswire
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study ...
- GlobeNewswire
Immunocore reports third quarter financial results and provides a business update
KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for ...
- GlobeNewswire
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Clinical data for first combination of ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings with a Buy and maintains $100 price target. ...
- GlobeNewswire
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical ...
- Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - IMMUNOCORE HOLDINGS PLC
Good afternoon, everyone. I'm Sean Larman, head of US Mid-Cap Biotech Equity Research here at Morgan Stanley, and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence, just to make you aware of so ...
- GlobeNewswire
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 ...
- GlobeNewswire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the ...
- Analyst Upgrades
JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target
JP Morgan analyst Jessica Fye reinstates Immunocore Holdings with a Overweight and announces $50 price target. ...
- Earnings Call Transcripts
Immunocore - Conference Call & Webcast - IMMUNOCORE HOLDINGS PLC
Greetings, and welcome to the Immunocore Conference Calling Webcast. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. You may be placed into quest ...
- GlobeNewswire
Immunocore reports second quarter financial results and provides a business update
Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM ...
- Analyst Upgrades
Mizuho Maintains Neutral on Immunocore Holdings, Raises Price Target to $35
Mizuho analyst Graig Suvannavejh maintains Immunocore Holdings with a Neutral and raises the price target from $34 to $35. ...
- GlobeNewswire
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (NASDAQ:IMCR) ...
- GlobeNewswire
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in ...
- GlobeNewswire
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings with a Buy and maintains $100 price target. ...
- GlobeNewswire
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings with a Buy and maintains $100 price target. ...
- GlobeNewswire
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or ...
- Analyst Upgrades
Jefferies Downgrades Immunocore Holdings to Hold, Lowers Price Target to $33
Jefferies analyst Clara Dong downgrades Immunocore Holdings from Buy to Hold and lowers the price target from $48 to $33. ...
- PR Newswire
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Equity-Insider.com News Commentary — The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress ... ...
- GlobeNewswire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 03 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a ...
- Analyst Upgrades
Needham Maintains Buy on Immunocore Holdings, Raises Price Target to $75
Needham analyst Gil Blum maintains Immunocore Holdings with a Buy and raises the price target from $71 to $75. ...
- GlobeNewswire
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating ...
- GlobeNewswire
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings ...